Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299562 | 1.00 | TACR1 (0.50) | TACR1IDO1TDO2TACR3 | |
| SCHEMBL13469371 | 0.91 | TACR1 (0.47) | TACR1IDO1TDO2TACR3 | |
| SCHEMBL12203906 | 0.84 | TACR1 (0.49) | TACR1IDO1TDO2TACR3 | |
| SCHEMBL12451725 | 0.84 | TACR1 (0.49) | TACR1IDO1TDO2TACR3 | |
| SCHEMBL13825745 | 0.83 | TACR1 (0.47) | TACR1IDO1TDO2TACR3 | |
| SCHEMBL24384391 | 0.79 | TACR1 (0.56) | TACR1TACR3 | |
| SCHEMBL19773685 | 0.79 | TACR1 (0.56) | TACR1TACR3 | |
| SCHEMBL437277 | 0.78 | TACR1 (0.42) | TACR1IDO1TDO2 | |
| SCHEMBL14291284 | 0.78 | TACR1 (0.55) | TACR1TACR3 | |
| SCHEMBL5205553 | 0.78 | TACR1 (0.55) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906085-B2 | Tetrahydropyran derivatives as neurokinin receptor antagonists | MERCK SHARP & DOHME LTD. | 2005-06-14 | — | — | US | disclosed |
| US-20040063974-A1 | Tetrahydropyran derivatives as neurokinin receptor antagonists | MERCK SHARP & DOHME, LTD. (GB) | 2004-04-01 | — | — | US | disclosed |
| US-20040023960-A1 | Mammalian metabolites of a tachykinin receptor antagonist | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | disclosed |
| EP-1331936-A2 | MAMMALIAN METABOLITES OF A TACHYKININ RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034699-A2 | MAMMALIAN METABOLITES OF A TACHYKININ RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063974-A1 | Tetrahydropyran derivatives as neurokinin receptor antagonists | NPSR1, OPRK1, CCKAR | TACR1 6/4885IDO1 406/4885TDO2 1080/4885 |
| US-20040023960-A1 | Mammalian metabolites of a tachykinin receptor antagonist | NTSR2, NTSR1, OPRL1 | TACR1 34/4885IDO1 386/4885TDO2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.